Leflunomide from Cayman Chemical

A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day